effect of pentoxifylline in COVID-19

Phase 3

Recruiting

• Conditions: Hypoxia due the mechanism of Covid-19.; Covid 19; U07.1

• Registration Number: IRCT20210623051677N1
• Lead Sponsor: Birjand University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 August 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

confirmation of Covid-19 diagnosis by PCR test
informed consent to participate in the study
No history of allergy to methylxanthines
Being hospitalized in the intensive care unit
The patient should not be intubated
arterial oxygen saturation less than 85% without oxygen therapy(room air or ambient air)

Exclusion Criteria

pregnancy and lactation
Severe liver failure
Severe renal failure
Bleeding disorder and coagulopathy
Hypersensitivity to the pentoxifylline(After prescribing)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Atrial of Oxygen saturation. Timepoint: Before the intervention and 48 hours,72 hours after the start of intervention. Method of measurement: Cardiac monitoring.;Measure of Arterial blood oxygen. Timepoint: Before the intervention and 48 hours,72 hours after the start of intervention. Method of measurement: ABG.;Blood pressure. Timepoint: Before the intervention and 48 hours,72 hours after the start of intervention. Method of measurement: Cardiac monitoring.

Secondary Outcome Measures

Name	Time	Method
Duration of hospitalization in Intensive care unit. Timepoint: Daily. Method of measurement: Check list.